Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share, payable April 22, 2026, to shareholders of record at the close of business March 31, 2026. The company said future dividend timing and amounts remain subject to board determination.
Financials: Agilent reported $6.95 billion revenue in fiscal 2025 and employs approximately 18,000 people worldwide.
Agilent (NYSE: A) awarded Boehringer Ingelheim the inaugural 2025 Instrument Trade‑In Impact Award for leading Agilent partners in sustainable trade‑in activity. In 2025 Boehringer Ingelheim diverted 6,600 kg of instrument waste from landfill via reuse, refurbishment, or proper recycling.
The award recognizes measurable progress toward a circular economy and supports Agilent’s programs to reduce laboratory waste and extend instrument lifecycles.
Agilent (NYSE: A) announced FDA approval of PD-L1 IHC 22C3 pharmDx, Code SK006 as the only FDA‑approved companion diagnostic to identify first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) patients whose tumors express PD‑L1 and may be eligible for KEYTRUDA.
This marks the seventh FDA companion diagnostic indication for the test and enables PD‑L1 assessment at diagnosis to support first‑line treatment decisions; Agilent reported $6.95 billion revenue in fiscal 2025.
Agilent (NYSE: A) will showcase next‑generation automated workflow solutions at SLAS2026 in Boston, Feb 7–11, 2026. The company will demo integrated imaging, robotics partnerships, AI‑driven CrossLab Connect enhancements, a new Cytation imaging platform preview, ProteoAnalyzer Software Security Module, and updated Bravo liquid‑handling protocols.
The exhibits include multi‑vendor integrations with ABB Robotics, HighRes Biosolutions, Biosero, and Unite Labs, two exhibitor tutorials, a spotlight presentation, and participation in conference panels.
Agilent (NYSE: A) will report first-quarter fiscal 2026 results after market close on Feb. 25, 2026 and will host a listen-only conference call/webcast at 1:30 p.m. PST the same day.
A recording will be available on the company's investor relations site for 90 days. Agilent reported $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE: A) launched the Agilent S540MD Slide Scanner System on January 23, 2026, a whole slide imaging scanner for high-volume digital pathology in key European markets. Engineered for speed and scalability, the system holds up to 540 slides, supports continuous loading, standard rack compatibility, automated scanning modes, and AI-assisted tissue detection. The scanner is an Agilent-branded version of the Hamamatsu NanoZoomer S540MD and will be available as IVD initially in Germany, France, Belgium, Spain, Austria, Luxembourg, Italy, the UK, and Switzerland, with further European expansion and milestones planned for 2026.
Crawford & Company (NYSE:A) announced a new global operating structure effective January 1, 2026, consolidating into two divisions: U.S. Operations and International Operations.
Mike Hoberman was promoted to CEO, U.S. Operations, reporting to interim President & CEO Bruce Swain. Canada will transition into International Operations under Andrew Bart. Pat Van Bakel was named chief commercial & strategy officer. New U.S. presidents named: Paul Kottler, Lance Malcolm and Jeffrey Sickles.
TORM plc (NASDAQ: TRMD) announced that the threshold date in its articles has occurred on 6 January 2026 after Hafnia's acquisition reduced Oaktree's stake below one-third.
As a result, the B-Director position and related authorities are extinguished, Deputy Chairman David Weinstein leaves the Board effective this date and will continue as Special Advisor. Article 137 limitations cease to have effect immediately. C-share voting rights for 350,000,000 shares have ceased; one B-share retains one vote until redemption. Voting rights now total 101,332,707 A-shares plus one B-share. Post-redemption share capital will be USD 1,013,327.07 divided into 101,332,707 A-shares of USD 0.01 each.
TORM plc (NASDAQ: TRMD / TRMD A) announced that Oaktree completed its acquisition of A shares on 22 December 2025. Following the transaction, Oaktree holds 26,425,059 A shares and Hafnia holds 14,156,061 A shares out of a total 101,332,707 A shares.
The board will now follow Article 5 of the Articles to determine the threshold date when Oaktree and affiliates first ceased to beneficially own at least one third of issued shares. On the threshold date the office of the B director, the C share voting rights and the limitations under Article 137 will cease to have effect, and the B and C share will be redeemed and cancelled. Further announcements will follow once processes conclude.
TORM plc (Nasdaq: TRMD / TRMD A) announced that the Board appointed Simon Mackenzie Smith as Chair of the Board, effective December 16, 2025, succeeding Chris Boehringer.
The change follows a planned succession process and the Board emphasized continuity and long‑term value creation for shareholders. Chris Boehringer, who served as Chair since 2015, will remain a Board member. The release highlights TORM's strengthened financial position and continued development of the One TORM platform during Boehringer's tenure.